Wednesday, September 28, 2022

Glenmark commemorates World Heart Month by organizing Public Hypertension Awareness Campaign in Mumbai with API, IMA-Mumbai West Region, and Malad Medical Association

- The campaign is aimed at increasing patient awareness about Heart Diseases as part of World Heart Month. 

- On the occasion, the world’s first ‘Hypertension Awareness Symbol’ was unveiled.

- Glenmark has planned 300 such rallies and >8000 screening camps for hypertension during the month.

- The company has partnered with more than 8000 doctors and 10,000 healthcare professionals from 42 cities across the country; and targets reaching out to more than 10 crore Indians.

Mumbai, India, September 28, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company, in partnership with Association of Physicians of India (API), Indian Medical Association (IMA) - Mumbai West region, and Malad Medical Association, launched a public awareness campaign at Suchak Hospital, Malad, Mumbai on 25th September to commemorate World Heart Month that falls in September. 

The event was graced by eminent guests including Mr. Gopal Shetty, Member of Parliament, North Mumbai, Ms. Sudha Chandran, popular dancer & television actress, Dr Agam Vora, Honorary General Secretary-API, Dr. Anil Suchak, Trustee- MMA (Malad Medical Association), Padma Shree awardee Dr. Shashank Joshi, Dr. K C Mehta, Dr. Rajesh Jain, President - MMA, Dr. Naresh Dandekar, Honorary General Secretary - MMA along with a pool of around 300 doctors. During the event, the world’s first ‘Hypertension Awareness Symbol’ conceptualized by Glenmark was unveiled. This symbol was developed in consultation with 50,000 leading doctors from across India with an aim to raise awareness of the growing burden of hypertension and the need for timely screening; and endorsed by API and Hypertension Society of India.  Following the event, an awareness rally was also organized in the region and was attended by several medical professionals, hospital staff and public.

Glenmark has planned 16 such rallies in Mumbai alone and more rallies across the country during the month of September. These country-wide rallies will emphasize on a detailed conversation on spreading awareness about Hypertension and its signs and symptoms followed by a mass hypertension screening camp. Being a leader in the hypertension therapeutic area, Glenmark is organizing 300 Hypertension public awareness rallies and more than 8000 hypertension screening camps throughout this month; and targets reaching out to more than 10 crore people. These rallies are being organized in association with various hospitals across the country. While 16 such rallies have been planned in Delhi, Kolkata and Mumbai; Chennai and Hyderabad have planned 12 awareness rallies. 

Speaking about the initiative, Alok Malik, Group Vice President & Head of India Formulations, Glenmark, said, “This initiative is our endeavor to create awareness about Hypertension in the country. Despite being a prevalent risk factor for cardiovascular diseases (CVD), Hypertension, remains to be a silent killer as majority of patients remain unaware of the condition.  As a leader in Hypertension management, Glenmark is committed to taking every possible step in the country’s fight against this disease, which affects millions of people every year.”

Glenmark has been leading from the front in increasing awareness and diagnosis of the disease among the Indian population. Not long ago, the company launched the #TakeChargeAt18 campaign to drive Hypertension awareness and screening of Indian adults above 18 years of age. The company has aims to reach out to more than 200 million Indian adults through multiple channels including its digital platform:

Hypertension (high blood pressure) is one of the biggest risk factors for heart disease, stroke and kidney disease. Every third adult in India is suffering from Hypertension- High blood pressure. Currently, it is estimated that 28.1% of all deaths in India were due to CVD, and high systolic blood pressure (SBP) was the single largest contributor (8.5%) to disability-adjusted life years (DALYs). A sustained combination of strategies can shift the population distribution of BP to the left and can help in achieving good control over it.  


About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit

Follow us on Social Media:

LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma

No comments: